BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29716606)

  • 1. The impact of orthopaedic research evidence on health financing in Australia.
    Hua M; Myers D; Host L
    Health Res Policy Syst; 2018 May; 16(1):36. PubMed ID: 29716606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health technology assessment in Australia: a role for clinical registries?
    Scott AM
    Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Horizon scanning of new and emerging medical technology in Australia: its relevance to Medical Services Advisory Committee health technology assessments and public funding.
    O'Malley SP; Jordan E
    Int J Technol Assess Health Care; 2009 Jul; 25(3):374-82. PubMed ID: 19619357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction and uptake of new medical technologies in the Australian health care system: a qualitative study.
    Gallego G; Casey R; Norman R; Goodall S
    Health Policy; 2011 Oct; 102(2-3):152-8. PubMed ID: 21601934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based funding of new imaging applications and technologies by Medicare in Australia: How it happens and how it can be improved.
    Hill H; Mittal R; Merlin T
    J Med Imaging Radiat Oncol; 2022 Mar; 66(2):215-224. PubMed ID: 35243777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of methods used in health technology assessments produced for the Medical Services Advisory Committee.
    Petherick ES; Villanueva EV; Dumville J; Bryan EJ; Dharmage S
    Med J Aust; 2007 Sep; 187(5):289-92. PubMed ID: 17767435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QUALITY OF HEALTH TECHNOLOGY ASSESSMENT REPORTS PREPARED FOR THE MEDICAL SERVICES ADVISORY COMMITTEE.
    Hua M; Boonstra T; Kelly PJ; Wilson A; Craig JC; Webster AC
    Int J Technol Assess Health Care; 2016 Jan; 32(4):315-323. PubMed ID: 27691988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A successful practical application of Coverage with Evidence Development in Australia: Medical Services Advisory Committee interim funding and the PillCam Capsule Endoscopy Register.
    O'Malley SP; Selby WS; Jordan E
    Int J Technol Assess Health Care; 2009 Jul; 25(3):290-6. PubMed ID: 19619347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Technology Assessment in Australia: The Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee.
    Kim H; Byrnes J; Goodall S;
    Value Health Reg Issues; 2021 May; 24():6-11. PubMed ID: 33429153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations.
    Yuba TY; Novaes HMD; de Soárez PC
    Health Res Policy Syst; 2018 May; 16(1):40. PubMed ID: 29751764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health economics and health technology assessment: perspectives from Australia and New Zealand.
    Streat S; Munn S
    Crit Care Clin; 2012 Jan; 28(1):125-33, vii. PubMed ID: 22123104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Power relations and contrasting conceptions of evidence in patient-involvement processes used to inform health funding decisions in Australia.
    Lopes E; Carter D; Street J
    Soc Sci Med; 2015 Jun; 135():84-91. PubMed ID: 25950114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of a decision by the Medical Services Advisory Committee based on health technology assessment of an emerging technology: the case for remotely assisted radical prostatectomy.
    O'Malley SP; Jordan E
    Int J Technol Assess Health Care; 2007; 23(2):286-91. PubMed ID: 17493316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.
    Guthrie S; Bienkowska-Gibbs T; Manville C; Pollitt A; Kirtley A; Wooding S
    Health Technol Assess; 2015 Aug; 19(67):1-291. PubMed ID: 26307643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Technology Assessments in Radiology in Germany: Lack of Demand, Lack of Supply.
    Winkelmann C; Neumann T; Zeidler J; Prenzler A; Vogt B; Wacker FK
    Rofo; 2019 Jul; 191(7):635-642. PubMed ID: 30763963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HTA responses and the classic HTA report.
    Milne R; Clegg A; Stevens A
    J Public Health Med; 2003 Jun; 25(2):102-6. PubMed ID: 12848397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Making recommendations to subsidize new health technologies in Australia: A qualitative study of decision-makers' perspectives on committee processes.
    Sellars M; Carter SM; Lancsar E; Howard K; Coast J
    Health Policy; 2024 Jan; 139():104963. PubMed ID: 38104371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.